ReviewMolecular neurodegeneration advances2026
Spilling the T: T cells in tauopathy mechanisms, disease progression, and therapeutic horizons.
Review in Molecular neurodegeneration advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Primary and secondary tauopathies are major causes of dementia characterized by the abnormal accumulation of microtubule-associated protein tau. Tau aggregation initiates neuronal dysfunction and death, while despite the distinct and pathological features of individual tauopathies, accumulating evidence shows that these disorders converge on shared mechanistic pathways marked by chronic inflammation and progressive neuronal loss. The innate immune response has been extensively studied in this context, yet the contribution of the adaptive immune system, particularly T cells, has only recently gained attention. In this review, we examine emerging evidence for adaptive immune involvement in tauopathies, including mechanisms that drive T cell activation and infiltration into the central nervous system, their effector functions once within the parenchyma, and how these responses interact with innate immune signaling. We also highlight potential therapeutic strategies aimed at modulating adaptive immunity in primary and secondary tauopathies. Current findings suggest that tau accumulation and glial-driven neuroinflammation creates an environment that promotes the activation and recruitment of effector T cells into the tauopathy brain. Importantly, blocking or reshaping the T cell responses shows promise for mitigating neurodegeneration, highlighting the adaptive immune system as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.